MedTrace Logo

Beta Blocker De-prescription Following Coronary Artery Bypass Graft Surgery (BEEFBURGER Trial).

NCT04788186 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2022-11-09

No results posted yet for this study

Summary

Beta-blockers have the greatest cardiovascular impact in patients with reduced heart function/heart failure and in reducing the peri-operative risk of atrial fibrillation. In patients without these high-risk features treated with coronary artery bypass graft (CABG) surgery, their continued long-term role is unclear.

Conditions

  • Coronary Artery Disease
  • Acute Myocardial Infarction
  • Coronary Artery Stenosis
  • ST Elevation Myocardial Infarction
  • Non-ST Elevation Myocardial Infarction (NSTEMI)

Interventions

DRUG

De-prescribe beta blocker therapy

Participants will be de-prescribed for beta-blocker therapy. De-prescription will be performed as follows: * Half of pre-randomization dose for the first 3 days, then * Half of the above dose for the next 3 days, then discontinue

Sponsors & Collaborators

  • Canadian VIGOUR Centre

    collaborator OTHER

  • University of Saskatchewan

    lead OTHER

Principal Investigators

  • Haissam Haddad, MD, FRCPC · University of Saskatchewan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-23
Primary Completion
2024-08-31
Completion
2025-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04788186 on ClinicalTrials.gov